Drug Use-results Survey of TEPMETKO tablets 250 mg (METex14 skipping alterations, unresectable, advanced or recurrent non-small cell lung cancer)
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000046465
- Lead Sponsor
- Merck Biopharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigate occurrence of interstitial lung disease, fluid retention, hepatic function disorder, renal impairment and QT interval prolongation
- Secondary Outcome Measures
Name Time Method